Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Raw Materials (2023 - 2025)

China SXT Pharmaceuticals (SXTC) has 3 years of Raw Materials data on record, last reported at $435799.0 in Q1 2025.

  • For Q1 2025, Raw Materials rose 35.88% year-over-year to $435799.0; the TTM value through Mar 2025 reached $435799.0, up 35.88%, while the annual FY2025 figure was $435799.0, 35.88% up from the prior year.
  • Raw Materials reached $435799.0 in Q1 2025 per SXTC's latest filing, up from $320722.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $435799.0 in Q1 2025 and bottomed at $243222.0 in Q1 2023.
  • Average Raw Materials over 3 years is $333247.7, with a median of $320722.0 recorded in 2024.
  • Peak YoY movement for Raw Materials: skyrocketed 31.86% in 2024, then surged 35.88% in 2025.
  • A 3-year view of Raw Materials shows it stood at $243222.0 in 2023, then surged by 31.86% to $320722.0 in 2024, then soared by 35.88% to $435799.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $435799.0 in Q1 2025, $320722.0 in Q1 2024, and $243222.0 in Q1 2023.